What are surrogate endpoints and how can they support the accelerated approval of new medicines?
Where and how are surrogate endpoints being used? In which disease areas and markets can their use help accelerate health technology assessment and market access? What guidance exists for the use of surrogate endpoints? How do you validate surrogate endpoints?
In this webinar, we explored the challenges and opportunities offered by the use of surrogate endpoints when presenting evidence and building health economic models to support global market access strategy and local reimbursement.
Watch to discover:
- What is a surrogate endpoint?
- When and how can surrogate endpoints be used to support timely market access and reimbursement?
- Where has guidance been published by national health technology assessment (HTA) agencies?
- How is surrogacy endpoint validation performed?
We also dive deep into an analysis of treatment effect correlation and work through a case study.
Request a copy of the slides:
If you would like a copy of the slides used in our Surrogate Endpoints webinar, please submit your details here.
Meet our speakers
Read our 2022 ISPOR poster assessing surrogate endpoints and their impact on HTA recommendations:
Learn more about our expertise in: